Vörös Krisztián, Cseh Károly, Kalabay László
Semmelweis Egyetem, Általános Orvostudományi Kar Családorvosi Tanszék Budapest Kútvölgyi út 4. 1125.
Semmelweis Egyetem, Általános Orvostudományi Kar Népegészségtani Intézet Budapest.
Orv Hetil. 2014 Jan 5;155(1):16-23. doi: 10.1556/OH.2014.29793.
Fetuin-A (also known as α2-Heremans-Schmid glycoprotein) is a multifunctional molecule secreted by the liver. It is a negative acute phase reactant with a debated role in subclinical inflammation. Fetuin-A is an inhibitor of the insulin receptor and its serum level correlates with insulin resistance. The protein has been implicated in adipocyte dysfunction and it is associated with obesity and non-alcoholic fatty liver disease. Although all these properties seem to promote atherosclerosis, the role of fetuin-A in cardiovascular diseases is more complex. As a natural inhibitor of tissue and vascular calcification, fetuin-A also acts as a protective factor in atherosclerosis. The potential role and prognostic value of fetuin-A in arterial calcification and cardiovascular diseases is discussed in this review, along with explanations for seemingly contradicting results in the literature and possible directions for future research.
胎球蛋白-A(也称为α2-赫雷曼斯-施密德糖蛋白)是肝脏分泌的一种多功能分子。它是一种负急性期反应物,在亚临床炎症中的作用存在争议。胎球蛋白-A是胰岛素受体的抑制剂,其血清水平与胰岛素抵抗相关。该蛋白与脂肪细胞功能障碍有关,并且与肥胖症和非酒精性脂肪性肝病相关。尽管所有这些特性似乎都促进动脉粥样硬化,但胎球蛋白-A在心血管疾病中的作用更为复杂。作为组织和血管钙化的天然抑制剂,胎球蛋白-A在动脉粥样硬化中也起到保护因子的作用。本文综述了胎球蛋白-A在动脉钙化和心血管疾病中的潜在作用及预后价值,同时解释了文献中看似相互矛盾的结果以及未来可能的研究方向。